Boston Scientific (NYSE:BSX) Price Target Lowered to $115.00 at Royal Bank Of Canada

Boston Scientific (NYSE:BSX) had its price target lowered by research analysts at Royal Bank Of Canada from $130.00 to $115.00 in a research report issued to clients and investors on Thursday, Marketbeat.com reports. The brokerage currently has an “outperform” rating on the medical equipment provider’s stock. Royal Bank Of Canada’s price objective indicates a potential upside of 46.98% from the stock’s current price.

A number of other brokerages also recently issued reports on BSX. The Goldman Sachs Group set a $99.00 price target on shares of Boston Scientific in a report on Thursday. Stifel Nicolaus decreased their price target on Boston Scientific from $125.00 to $110.00 and set a “buy” rating on the stock in a research note on Wednesday. Truist Financial reduced their price objective on shares of Boston Scientific from $120.00 to $95.00 and set a “buy” rating on the stock in a report on Thursday. Robert W. Baird lowered their target price on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a research note on Thursday. Finally, TD Cowen decreased their price objective on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a report on Monday. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Boston Scientific presently has an average rating of “Moderate Buy” and an average price target of $110.86.

Boston Scientific Trading Up 3.6%

NYSE BSX traded up $2.74 on Thursday, reaching $78.24. 22,271,856 shares of the company were exchanged, compared to its average volume of 15,930,081. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The business’s fifty day moving average price is $94.37 and its 200 day moving average price is $99.13. The stock has a market capitalization of $115.99 billion, a P/E ratio of 41.86, a price-to-earnings-growth ratio of 1.63 and a beta of 0.67. Boston Scientific has a fifty-two week low of $74.86 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02. The business had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The company’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts forecast that Boston Scientific will post 2.85 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Boston Scientific

Institutional investors and hedge funds have recently made changes to their positions in the stock. Brighton Jones LLC lifted its stake in Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares during the last quarter. Belpointe Asset Management LLC raised its holdings in shares of Boston Scientific by 119.4% in the 2nd quarter. Belpointe Asset Management LLC now owns 5,048 shares of the medical equipment provider’s stock valued at $542,000 after purchasing an additional 2,747 shares in the last quarter. Venturi Wealth Management LLC lifted its position in shares of Boston Scientific by 8.0% during the 2nd quarter. Venturi Wealth Management LLC now owns 8,866 shares of the medical equipment provider’s stock worth $952,000 after purchasing an additional 654 shares during the last quarter. REAP Financial Group LLC grew its stake in shares of Boston Scientific by 179.1% during the second quarter. REAP Financial Group LLC now owns 494 shares of the medical equipment provider’s stock worth $53,000 after purchasing an additional 317 shares in the last quarter. Finally, NBT Bank N A NY increased its holdings in Boston Scientific by 4.1% in the second quarter. NBT Bank N A NY now owns 3,842 shares of the medical equipment provider’s stock valued at $413,000 after buying an additional 153 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 results beat expectations — EPS $0.80 vs. $0.78 consensus and revenue $5.29B (+15.9% year/year), with margin improvements and solid organic growth. This underpins the company’s longer-term growth story. Boston Scientific announces results for fourth quarter and full year 2025
• Positive Sentiment: Long-term research coverage highlights BSX as a growth stock based on Zacks style scores — a supportive narrative for buy-and-hold investors focused on medical-device secular trends. Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
• Neutral Sentiment: Multiple analysts cut price targets after the print but largely kept buy/overweight ratings — signaling confidence in the franchise but tempered near-term estimates. The headline impact is mixed: sells on caution, but continued analyst support limits downside. Boston Scientific Analysts Cut Their Forecasts Following Q4 Results
• Negative Sentiment: Management’s modest FY2026 revenue and EPS guidance, plus softer-than-expected electrophysiology sales, sparked a large intra-day sell-off (stock plunged double-digits after the report) as investors reset growth expectations. That guidance concern remains the primary driver of recent weakness. Boston Scientific shares slide on cautious 2026 revenue forecast
• Negative Sentiment: Elevated bearish activity and insider selling add pressure — options flow showed a spike in put buying around the print, and CEO Michael Mahoney disclosed a large sale of ~160,901 shares, which can amplify short-term negative sentiment. Insider Selling: Boston Scientific (NYSE:BSX) CEO Sells 160,901 Shares of Stock

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.